Adverum Biotechnologies, Inc.
ADVM
$4.17
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.25% | -58.64% | -41.75% | -23.26% | 5.96% |
| Total Depreciation and Amortization | -35.28% | -34.73% | -33.87% | -35.28% | -39.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.04% | 4.72% | 16.44% | 23.69% | 0.29% |
| Change in Net Operating Assets | 6,263.70% | 400.51% | 236.02% | 244.13% | -126.09% |
| Cash from Operations | -61.21% | -48.21% | -22.08% | -1.72% | 2.85% |
| Capital Expenditure | -4.62% | 21.56% | 36.29% | 51.98% | 35.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 230.47% | 403.58% | -77.95% | -142.49% | -142.86% |
| Cash from Investing | 227.90% | 384.68% | -78.58% | -143.24% | -143.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.46% | -99.70% | -99.80% | 24,464.21% | 24,464.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 77.91% |
| Cash from Financing | -91.45% | -99.70% | -99.90% | 173,817.39% | 82,610.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -406.41% | -649.18% | -223.20% | -337.47% | -162.56% |